4 completed, 3 recruiting, 3 unknown. 10 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 4, Recruiting 3, Unknown 3 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Cardiogenic Shock: new trials by email Literature Review of Cardiogenic Shock trials Research Report on Cardiogenic Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock istaroxime, placebo - Cardiogenic Shock | Phase 2 / Phase 3 | Recruiting | Seismic Pharmaceuticals Operations LLC | 600 | 2026-09-09 | 2026-09-23 |
| Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. Empagliflozin 10 MG - Cardiogenic Shock | Phase 3 | Recruiting | Central Hospital, Nancy, France | 164 | 2024-12-16 | 2025-06-27 |
| Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock Levosimendan 2.5 MG/ML Injectable Solution, Placebo - Cardiogenic Shock | Phase 3 | Recruiting | Pr Bruno LEVY | 610 | 2023-07-03 | 2025-08-05 |
| Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support Ivabradine 7.5Mg Tab, DOBUTamine Injectable Solution - Heart Failure, Cardiogenic Shock | Phase 3 | Unknown | The Young Investigator Group of Cardiovascular Research | 200 | 2022-07-01 | 2022-10-26 |
| Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock Oxygen gas - Cardiogenic Shock, Extracorporeal Membrane Oxygenation | Phase 3 | Completed | Centre Hospitalier Universitaire de Besancon | 60 | 2022-01-09 | 2024-12-30 |
| LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients Levosimendan, Placebo of Levosimendan - Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 206 | 2021-08-27 | 2025-03-21 |
| Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. Hydrocortisone + Flucortac, Placebo - Cardiogenic Shock | Phase 3 | Completed | CMC Ambroise Paré | 380 | 2019-04-19 | 2026-05-19 |
| Adrecizumab in Cardiogenic Shock Adrecizumab, Placebo - Cardiogenic Shock, Endothelial Dysfunction | Phase 2 / Phase 3 | Completed | Dr. med. Mahir Karakas | 150 | 2019-04-04 | 2021-10-08 |
| Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock Norepinephrine - Cardiogenic Shock | Phase 3 | Unknown | Central Hospital, Nancy, France | 40 | 2018-01-15 | 2017-11-14 |
| Levosimendan Versus Dobutamine in Shock Patients Levosimendan, Dobutamine - Cardiogenic Shock, Septic Shock | Phase 2 / Phase 3 | Unknown | Wentworth Area Health Services | 40 | 2004-10-01 | 2005-06-24 |
Shock, Cardiogenic (10) · Heart Failure (4) · Shock (2) · Adrenal Insufficiency (1) · Hyperoxia (1) · Myocardial Ischemia (1) · Sepsis (1) · Shock, Septic (1)
Cardiovascular Diseases (10) · Heart Diseases (10) · Infarction (10) · Ischemia (10) · Myocardial Infarction (10) · Necrosis (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Vascular Diseases (10) · Myocardial Ischemia (9) · Shock (8) · Adrenal Gland Diseases (1) · Endocrine System Diseases (1) · Infections (1) · Inflammation (1)
Dobutamine (3) · Simendan (3) · Hydrocortisone (1) · Istaroxime (1) · Ivabradine (1) · Norepinephrine (1) · Sodium Chloride (1) · empagliflozin (1) · enibarcimab (1) · nitrox (1)
Central Hospital, Nancy, France (2) · Assistance Publique - Hôpitaux de Paris (1) · CMC Ambroise Paré (1) · Centre Hospitalier Universitaire de Besancon (1) · Dr. med. Mahir Karakas (1) · Pr Bruno LEVY (1) · Seismic Pharmaceuticals Operations LLC (1) · The Young Investigator Group of Cardiovascular Research (1) · Wentworth Area Health Services (1)
France (6) · Armenia (1) · Australia (1) · Egypt (1) · Germany (1)
Gabe Coitler (1) · Mahir Karakas, MD, MBA (1)
PMID 23322670, PMID 28506763, PMID 28787294, PMID 30966908, PMID 34895483, PMID 34980224, PMID 41324946
2017 (1), 2019 (1)